BR112012005834A2 - processo de síntese da ivabradina e de seus sais de adição a um ácido farmaceuticamente aceitável - Google Patents

processo de síntese da ivabradina e de seus sais de adição a um ácido farmaceuticamente aceitável

Info

Publication number
BR112012005834A2
BR112012005834A2 BR112012005834A BR112012005834A BR112012005834A2 BR 112012005834 A2 BR112012005834 A2 BR 112012005834A2 BR 112012005834 A BR112012005834 A BR 112012005834A BR 112012005834 A BR112012005834 A BR 112012005834A BR 112012005834 A2 BR112012005834 A2 BR 112012005834A2
Authority
BR
Brazil
Prior art keywords
ivabradine
pharmaceutically acceptable
addition salts
acceptable acid
synthesis process
Prior art date
Application number
BR112012005834A
Other languages
English (en)
Inventor
Jean-Louis Peglion
Jean-Michel Lerestif
Jean-Pierre Lecouve
Pascal Caignard
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of BR112012005834A2 publication Critical patent/BR112012005834A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

processo de síntese da ivabradina e de seus sais de adição a um ácido farmaceuticamente aceitável. a presente invenção refere-se a processo de síntese da ivabradina de fórmula (i) e de seus sais de adição a um ácido farmaceuticamente aceitável.
BR112012005834A 2009-09-18 2010-09-17 processo de síntese da ivabradina e de seus sais de adição a um ácido farmaceuticamente aceitável BR112012005834A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0904463A FR2950343B1 (fr) 2009-09-18 2009-09-18 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PCT/FR2010/000625 WO2011033194A1 (fr) 2009-09-18 2010-09-17 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Publications (1)

Publication Number Publication Date
BR112012005834A2 true BR112012005834A2 (pt) 2015-09-08

Family

ID=42245545

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005834A BR112012005834A2 (pt) 2009-09-18 2010-09-17 processo de síntese da ivabradina e de seus sais de adição a um ácido farmaceuticamente aceitável

Country Status (20)

Country Link
US (1) US20120172589A1 (pt)
EP (1) EP2477970A1 (pt)
JP (1) JP2013505225A (pt)
KR (1) KR101416595B1 (pt)
CN (1) CN102498102A (pt)
AR (1) AR078179A1 (pt)
AU (1) AU2010297176B2 (pt)
BR (1) BR112012005834A2 (pt)
CA (1) CA2773064C (pt)
EA (1) EA019380B1 (pt)
FR (1) FR2950343B1 (pt)
GE (1) GEP20146019B (pt)
MA (1) MA33580B1 (pt)
MX (1) MX2012002818A (pt)
MY (1) MY169295A (pt)
NZ (1) NZ598354A (pt)
SG (1) SG178532A1 (pt)
UA (1) UA106386C2 (pt)
WO (1) WO2011033194A1 (pt)
ZA (1) ZA201201329B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212026B2 (en) 2007-05-30 2012-07-03 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
FR2988720B1 (fr) * 2012-03-27 2014-03-14 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN102827019B (zh) * 2012-09-12 2014-12-10 江苏宇田生物医药科技有限公司 一组新的苯并环丁烷化合物及其在化学合成中的应用
CN103848789B (zh) * 2012-11-29 2016-05-18 江苏恒瑞医药股份有限公司 一种伊伐布雷定的制备方法
CN104447553B (zh) * 2013-09-22 2017-02-01 广东众生药业股份有限公司 伊伐布雷定及其中间体的制备方法
CN103772281B (zh) * 2013-12-31 2015-10-21 南京正大天晴制药有限公司 伊伐布雷定的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
EP2097383B1 (en) * 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
US8212026B2 (en) * 2007-05-30 2012-07-03 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
FR2956401B1 (fr) * 2010-02-17 2012-02-03 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Also Published As

Publication number Publication date
ZA201201329B (en) 2013-05-29
UA106386C2 (ru) 2014-08-26
CN102498102A (zh) 2012-06-13
KR101416595B1 (ko) 2014-07-08
FR2950343B1 (fr) 2011-11-18
GEP20146019B (en) 2014-01-27
CA2773064A1 (fr) 2011-03-24
AU2010297176B2 (en) 2013-05-16
MA33580B1 (fr) 2012-09-01
EA201200498A1 (ru) 2012-10-30
MX2012002818A (es) 2012-04-19
US20120172589A1 (en) 2012-07-05
WO2011033194A1 (fr) 2011-03-24
JP2013505225A (ja) 2013-02-14
AR078179A1 (es) 2011-10-19
EP2477970A1 (fr) 2012-07-25
SG178532A1 (en) 2012-03-29
FR2950343A1 (fr) 2011-03-25
CA2773064C (fr) 2014-09-02
EA019380B1 (ru) 2014-03-31
MY169295A (en) 2019-03-21
NZ598354A (en) 2013-03-28
KR20120064708A (ko) 2012-06-19
AU2010297176A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
BR112012005834A2 (pt) processo de síntese da ivabradina e de seus sais de adição a um ácido farmaceuticamente aceitável
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
MX2011007978A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
BRPI0817747A8 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
MX2010003213A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2010003184A (es) Nuevo procedimiento de sinstesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
IN2012DE00289A (pt)
BR112013006720A2 (pt) processo para preparação de inibidores de pan-cdk da fórmula (i) e intermediários da preparação
UA106208C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
BR112013017307A2 (pt) processo de síntese da agomelatina
BR112012012905A2 (pt) derivados de difenil azepina como inibidores da reabsorção de monoamina
MX2011012233A (es) Soluciones de retinoide topicas.
BR102013031270A8 (pt) processo para a síntese de 3-(2-bromo-4,5-dimetoxifenil) propanonitrila, e aplicação na síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
BR112013005225A2 (pt) "processo para preparação de ditiina-tetracarboximidas".
MX2013002990A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
IN2013CN00515A (pt)
BRPI0514076A (pt) processo de preparação da n-aminopiperidina e de seus sais
BR112013017264A2 (pt) processo de síntese da agomelatina
SG165255A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL